Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Iron Dextran in AKI with Iron Deficiency
NCT05960227Phase 2Completed
- Sponsor
- Hospital Civil de Guadalajara
- Start
- Jan 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in iron deficiency anemia (IDA) and acute kidney injury (AKI) comparing Iron dextran IV with Placebo (2 arms). Primary endpoint: Renal function estimated in GFR at 3 months. Started Jan 2023; status: completed.
02
Drugs
iron dextran
03
Conditions
iron deficiency anemia (IDA)acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05960227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05960227.